NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Harmony Biosciences reported strong financial results in the third quarter of 2024, driven by WAKIX sales and pipeline advancements.
Harmony Biosciences reported a record $186.0 million in net revenue for Q3 2024. The company is on track to submit an sNDA for pitolisant in Idiopathic Hypersomnia in Q4 2024. They reiterated their 2024 net product revenue guidance of $700 - $720 million.
- Net product revenues for the quarter were $186.0 million, compared to $160.3 million for the same period in 2023.
- GAAP net income for the quarter was $46.1 million, or $0.79 earnings per diluted share.
- Non-GAAP adjusted net income was $59.6 million, or $1.03 earnings per diluted share.
- Harmony had cash, cash equivalents and investments of $504.7 million as of September 30, 2024.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$186M
Revenue by segment
Harmony Biosciences · $160M total across 1 segment · Q3 2023
- WAKIX Net Product Revenue$160M+36.8%100.0%
Forward guidance
Harmony Biosciences expects full year 2024 net product revenue of $700 million to $720 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro